

CA OPIOID SETTLEMENTS
EXPENDITURE REPORTING FORM

SFY 2023 - 2024

**Prepared on 2025-12-04 by the University of
California, Los Angeles**

Integrated Substance Use and Addictions Programs



CONTENTS

GENERAL INFORMATION	1
CA ABATEMENT ACCOUNT FUNDS INFORMATION	1
CA Abatement Payments:	1
CA Abatement Reallocations:	2
CA Abatement Expenditures:	2
Activity#1	2
Activity#2	3
Activity#3	4
CA SUBDIVISION FUND INFORMATION	6
CA Subdivision Fund Payments:	6
CA Subdivision Fund Reallocations:	7
CA Subdivision Fund Future Opioid-Related Expenditures:	7
Activity#1	7
Activity#2	7
CA Subdivision Fund Reimbursements & Past Legal Expenses:	8
MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION	8
Mallinckrodt Bankruptcy Payments:	9

Mallinckrodt Reallocations:	9
Mallinckrodt Allowable Expenses:	9
SUMMARY	11

GENERAL INFORMATION

Participating Subdivision: Marin County
Subdivision Department/Organization: Department of Health and Human Services
Subdivision address: 20 N. San Pedro Rd. San Rafael CA 94903
Name of Preparer: Kam Lam
Preparer Title: Senior Department Analyst
Preparer Email Address: kam.lam@marincounty.gov
Preparer Phone Number: 415-473-2739
This Subdivision received funds from:
Settlements & Mallinckrodt Pharmaceuticals Bankruptcy

CA ABATEMENT ACCOUNT FUNDS INFORMATION

- Settlement(s):**
- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
 - Janssen Pharmaceuticals, Inc.

CA Abatement Payments:

Payments Received by this Subdivision from the CA Abatement Account Fund

Settlement	CA Abatement Account Payments Received in SFY 23-24
Distributors	\$484,902.97
Janssen	\$219,074.67

Is your Participating Subdivision depositing CA Abatement Accounts Fund payments from the National Settlement Administrator (Brown-Greer, PLC) into an interest-bearing account?: Yes

Interest Earned from the CA Abatement Account Fund

Settlement	CA Abatement Account Interest Earned in SFY 23-24
Distributors	\$36,430.03
Janssen	\$23,913.92

CA Abatement Reallocations:

Reallocations Sent: No funds received from the CA Abatement Account were reallocated to another Subdivision.

Reallocations Received: No funds received from the CA Abatement Account were reallocated from another Subdivision.

CA Abatement Expenditures:

How many total activities or programs funded by the funds from the CA Abatement Accounts Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?: 3

Activity#1

Activity or Program Name: Naloxone (Narcan) Supplies

Activity or Program Description: Purchased 1,564 cartons of Naloxone (Narcan), the opioid overdose reversal medication, for countywide distribution.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$50,876.42	\$0.00	\$0.00
Janssen	\$16,581.19	\$0.00	\$0.00

Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?: No

Activity Start Date (mm/dd/yyyy): 09/06/2023

All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:

N/A

Allowable Expenditure Category: Prevent Overdose Deaths and Other Harms (Harm Reduction)

High Impact Abatement Activity (HIAA) Category

HIAA Satisfied	Reasoning
HIAA 6: The purchase of naloxone for distribution and efforts to expand access to naloxone for opioid overdose reversals Please describe:	The goal of OD Free Marin is to reduce and eventually eliminate overdose deaths in Marin County. A key strategy is the distribution of Naloxone to all segments of our population with relevant education to ensure general public bystanders can become first responders to administer the life-saving medication in case of overdose in their vicinity.

Activity#2

Activity or Program Name: OD Free Marin Staffing Support

Activity or Program Description: Hired a full-time Senior Program Coordinator position to manage the growing deliverables for OD Free Marin including: expanding community prevention strategies; overseeing data management, including internal program evaluation and public-facing reporting; engaging stakeholders and partners locally, statewide and nationally; managing growing number of volunteers; and overseeing all communications on various platforms.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$105,823.33	\$0.00	\$0.00
Janssen	\$0.00	\$0.00	\$0.00

Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?: No

Activity Start Date (mm/dd/yyyy): 08/20/2023

All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:

N/A

Allowable Expenditure Category: Leadership, Planning and Coordination

This activity does not meet the criteria to be a High Impact Abatement Activity.

Activity#3

Activity or Program Name: Training and Distribution of Naloxone (Narcan) to vulnerable populations

Activity or Program Description: Hired two part time Graduate Student Interns for the training and distribution of Naloxone (Narcan). Interns distribute Naloxone (Narcan) to vulnerable populations with a focus on Youth and the recovery community.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$52,627.41	\$0.00	\$0.00
Janssen	\$0.00	\$0.00	\$0.00

Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?: No

Activity Start Date (mm/dd/yyyy): 10/29/2023

All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:

N/A

Allowable Expenditure Category: Prevent Overdose Deaths and Other Harms (Harm Reduction)

High Impact Abatement Activity (HIAA) Category

HIAA Satisfied	Reasoning
HIAA 6: The purchase of naloxone for distribution and efforts to expand access to naloxone for opioid overdose reversals Please describe:	Two part time Graduate Student Inters distribute Naloxone (Narcan) to vulnerable populations with a focus on Youth and the recovery community.

CA SUBDIVISION FUND INFORMATION

Is your Participating Subdivision also a Plaintiff Subdivision?: Yes

- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
- Janssen Pharmaceuticals, Inc.

CA Subdivision Fund Payments:

Payments Received by this Plaintiff Subdivision from the CA Subdivision Fund

Settlement	CA Subdivision Fund Payments Received in SFY 23-24
Distributors	\$112,547.25
Janssen	\$50,847.80

Is your Participating Subdivision depositing CA Subdivision Fund payments from the National Settlement Administrator (BrownGreer, PLC) into an interest-bearing account?: Yes

Interest Earned from the CA Subdivision Fund

Settlement	CA Subdivision Fund Interest Earned in SFY 23-24
Distributors	\$9,354.07
Janssen	\$5,540.42

CA Subdivision Fund Reallocations:

Reallocations Sent: No funds received from the CA Subdivision Fund were reallocated to another Subdivision.

Reallocations Received: No funds received from the CA Subdivision Fund were reallocated from another Subdivision.

CA Subdivision Fund Future Opioid-Related Expenditures:

How many total activities or programs were funded by funds from the CA Subdivision Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?: 2

Activity#1

Activity or Program Name: Naloxone (Narcan) Supplies

Activity or Program Description: Purchased 56 cartons of Naloxone (Narcan), the opioid overdose reversal medication, for countywide distribution.

Activity Expenditures

Settlement	Funds Expended (SFY 23-24)
Distributors	\$0.00
Janssen	\$2,542.39

Allowable Expenditure Category:

1 – Address the misuse and abuse of opioid products.

Activity#2

Activity or Program Name: OD Free Marin Staffing Support

Activity or Program Description: Hired a full-time Senior Program Coordinator position to manage the growing deliverables for OD Free Marin

including: expending community prevention strategies; overseeing data management, including internal program evaluation and public-facing reporting; engaging stakeholders and partners locally, statewide and nationally; managing growing number of volunteers; and overseeing all communications on various platforms.

Activity Expenditures

Settlement	Funds Expended (SFY 23-24)
Distributors	\$32,843.59
Janssen	\$0.00

Allowable Expenditure Category:

1 – Address the misuse and abuse of opioid products.

CA Subdivision Fund Reimbursements & Past Legal Expenses:

During SFY 23-24, did your Plaintiff Subdivision use settlement funds to cover past legal expenses related to opioid litigation?: No

During SFY 23-24, did your Plaintiff Subdivision use settlement funds to cover reimbursements for past opioid-related expenses spent prior to the receipt of settlement funds?: No

MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION

Did your Local Government receive funds from the Mallinckrodt Bankruptcy (NOAT II)?: Yes

Mallinckrodt Bankruptcy Payments:

Total amount of funds received from NOAT II from July 1, 2023 – June 30, 2024:

\$67,647.12

Is your Local Government depositing Mallinckrodt Bankruptcy payments from NOAT II into an interest-bearing account?

Yes

Total amount of Interest earned from NOAT II from July 1, 2023 – June 30, 2024:

\$4,050.95

Mallinckrodt Reallocations:

Reallocations Sent:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated to another Subdivision.

Reallocations Received:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated from another Subdivision.

Mallinckrodt Allowable Expenses:

Did your Local Government expend any bankruptcy funds during the period of July 1, 2023 – June 30, 2024?: Yes

Mallinckrodt Allowable Expenses Breakdown

Approved Category	Direct Costs July - Dec. 2023	Direct Costs Jan. - June 2024	Indirect Costs July - Dec. 2023	Indirect Costs Jan - June 2024
Schedule A.I.Evidence-Based Data Collection and Research Analyzing the Effectiveness of the Abatement Strategies Within the State	\$0.00	\$7,403.50	\$0.00	\$0.00
Schedule A.A. Naloxone or Other FDA-Approved Drug to Reverse Opioid Overdoses	\$0.00	\$6,710.09	\$0.00	\$0.00
Schedule A.G. Prevention Programs	\$0.00	\$12,000.00	\$0.00	\$0.00

SUMMARY

All tables below are based on information reported during the SFY 2023-24 only.

CA Abatement Account Fund Totals

Settlement	Payment	Interest	Reallocations Sent	Reallocations Received
Distributors	\$484,902.97	\$36,430.03	\$0.00	\$0.00
Janssen	\$219,074.67	\$23,913.92	\$0.00	\$0.00
Total	\$703,977.64	\$60,343.95	\$0.00	\$0.00

CA Abatement Account Activity Expenses

Settlement	Activity Expenses	Indirect Costs	23/24 Encumbered Funds	22/23 Encumbered Funds
Distributors	\$209,327.16	\$0.00	\$0.00	\$0.00
Janssen	\$16,581.19	\$0.00	\$0.00	\$0.00
Total	\$225,908.35	\$0.00	\$0.00	\$0.00

CA Subdivision Fund Totals

Settlement	Payment	Interest	Reallocation Sent	Reallocation Received
Distributors	\$112,547.25	\$9,354.07	\$0.00	\$0.00
Janssen	\$50,847.80	\$5,540.42	\$0.00	\$0.00
Total	\$163,395.05	\$14,894.49	\$0.00	\$0.00

CA Subdivision Fund Expenses

Settlement	Activity Expense	Legal Expenses	Reimbursed Activity Expense
Distributors	\$32,843.59	\$0.00	\$0.00
Janssen	\$2,542.39	\$0.00	\$0.00
Total	\$35,385.98	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Totals

Payment	Interest	Reallocations Sent	Reallocations Received
\$67,647.12	\$4,050.95	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Expenses

Direct Costs	Indirect Costs
\$26,113.59	\$0.00